Effects of betaxolol and flunarizine on visual fields and intraocular pressure in patients with migraine

Documenta Ophthalmologica

Volumn 106, Issue 3, 2003, Pages 265-270

  Yarangümeli, Alper ^a   Çomoglu, Selçuk ^a   Köz, Özlem Gürbüz ^a   Elhan, Atilla Halil ^b   Kural, Gülcan ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Betaxolol; Flunarizine; Intraocular pressure; Migraine; Visual field

Indexed keywords

BETAXOLOL; CALCIUM CHANNEL BLOCKING AGENT; FLUNARIZINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EYE IRRITATION; FEMALE; FOLLOW UP; HEART PALPITATION; HUMAN; INCREASED APPETITE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MIGRAINE; ORGAN PERFUSION; PRESCRIPTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SYSTEMIC THERAPY; VASOSPASM; VISUAL FIELD; VISUAL FIELD DEFECT; WEIGHT GAIN;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; BETAXOLOL; CALCIUM CHANNEL BLOCKERS; DRUG THERAPY, COMBINATION; FEMALE; FLUNARIZINE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; MIGRAINE DISORDERS; VISUAL FIELDS;

EID: 0344951176     PISSN: 00124486     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022925432197     Document Type: Article

References (34)

1. Gasser P. Ocular vasospasm: A risk factor in the pathogenesis of low-tension glaucoma. Int Ophthalmol 1989; 13: 281-5.
2. Broadway DC, Drance SM. Glaucoma and vasospasm. Br J Ophthalmol 1998; 82: 862-70.
3. Guthauser U, Flammer J, Mahler F. The relationship between digital and ocular vasospasm. Graefe's Arch Clin Exp Ophthalmol 1988; 226: 224-6.
4. Gasser P, Flammer J, Guthauser U, Mahler F. Do vasospasms provoke ocular diseases? Angiology 1990; 41: 213-20.
5. Gasser P, Flammer J. Influence of vasospasm on visual function. Doc Ophthalmol 1987; 66: 3-18.
6. Wang JJ, Mitchell P, Smith W. Is there an association between migraine headache and open-angle glaucoma? Findings from the Blue Mountains Eye Study. Ophthalmology 1997; 104: 1714-9.
7. Phelps CD, Corbett JJ. Migraine and low-tension glaucoma. A case-control study. Invest Ophthalmol Vis Sci 1985; 26: 1105-8.
8. Lewis RA, Vijayan N, Watson C, Keltner J, Johnson CA. Visual field loss in migraine. Ophthalmology 1989; 96: 321-6.
9. Campbell JK, Caselli RJ. Headache and other craniofacial pain. In: Bradley WG, Daroff RB, Fenichel GM, Marsden CD, eds. Neurology in Clinical Practice, vol. 2. Stoneham: Butterworth-Heinemann, 1989; 2: 1520-31.
10. Netland PA, Chanturued N, Dreyer EB. Calcium channel blockers in the management of low tension and OAG. Am J Ophthalmol 1993; 115: 608-13.
11. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl 7): 1-96.
12. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs 1998; 56: 811-24.
13. Drance SM, Douglas GR, Wijsman K, Schulzer M, Birttan RJ. Response of blood flow to warm and cold in normal and low-tension glaucoma patients. Am J Ophthalmol 1988; 105: 35-9.
14. Bono G, Manzoni GC, Martucci N, Baldrati A, Garina S, Cassabgi F, De Carolis P, Nappi G. Flunarizine in common migraine: Italian cooperative trial. II. Long-term follow-up. Cephalalgia 1985; 5 (Suppl 2): 155-8.
15. Schumer RA, Podos SM. The nerve of glaucoma. Arch Ophthalmol 1994; 112: 37-44.
16. Caprioli J. Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol Scand 1997; 75: 364-7.
17. Netland PA, Cynthia LG, Feke GT, Hart LJ. Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am J Ophthalmol 1995; 119: 694-700.
18. Kitazawa Y, Shiari H, Go FS. The effect of calcium antagonist on visual field low in tension glaucoma. Graefes Arch Clin Exp Ophthalmol 1989; 227: 408-12.
19. Harris A, Evans DW, Contor LB, Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal tension glaucoma. Am J Ophthalmol 1997; 124: 296-302.
20. Yamamato T, Niva Y, Kavakami H, Kitazawa Y. The effect of nilvadipine, a calcium channel blocker, on the hemodynamics of retrobulber vessels in normal tension glaucoma. J Glaucoma 1998; 7: 301-5.
21. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica 1995; 209: 11-3
22. Petreus JP, Leysen JE, Janssen PAJ. Calcium and sodium channels involved in neuronal cell death protection by flunarizine. Life Science 1991; 48: 1881-93.
23. Urenjak J, Obrenovitch O. Neuroprotective drugs presumbly acting on sodium channels. J Pharmacol Rev 1996; 21: 47-50.
24. Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: The clinical experience. J Cardiovasc Pharmacol 1991; 18: 21-6.
25. Ryck MD, Reempty JV, Borgers M. Photoreceptor stroke model flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke 1989; 20: 1383-90.
26. Alps BJ, Hass WK, Wilson AD. Comparative protective effects of nicardipine, flunarizine, lidoflazine and nimodipine agonist ischaemic injury in the hipocampus of the mongolian gerbil. Br J Ophthalmol 1988, 93: 877-83.
27. Peters T, Wilffert B, Van Houtte PM, Van Zwiete PA. Calcium channel in the brain as targets for the calcium channel modulators used in the treatment of neurological disorders. J Cardiovasc Pharmacol 1991; 18 (Suppl): S1-5.
28. Lam TT, Fu J, Mrynewycz M, Tso MO. The effect of carboxylic acid an endonuclease inhibitor on ischemia/reperfusion damage in rat retina. J Ocul Pharmacol Ther 1995; 11: 253-9.
29. Cellini M, Possati GL, Caramazza N, Profazio U, Caramazza R. The use of flunarizine in the management of low tension glaucoma. A color Doppler study. Acta Ophthalmol Scand 1997; 224: 57-65.
30. Collignon-Brunch J. Long term effect of topical beta blockers on intraocular pressure and visual field sensitivity in ocular hypertension and COAG. Surv Ophthalmol 1994; 38: 149-55.
31. Turaçli ME, Özden RG, Gürses MA. The effect of betaxolol on ocular blood flow and visual fields in patients with normotension glaucoma. Eur J Ophthalmol 1998; 8: 62-6.
32. Yu D, Su E, Cringle S, Alder V, Yu P, DeSantis L. Systemic and ocular vascular roles of the antiglaucoma agents β-adrenergic antagonists and Ca entry blockers. Surv Ophthalmol 1999; 43 (Suppl): S214-222.
33. Osborne NN, Ugarte M, Chao M, Chidlow G, Bae JH, Wood JP, Nash MS. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol 1999; 43 (Suppl): S102-28.
34. Wöber C, Wöber-Bingöl C, Koch G, Wessely P Long-term results of migraine prophylaxis with flunarizine and beta-blockers. Cephalalgia 1991; 11: 251-6.